Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28205108 | 0.87 | FUCA1 (0.40) | ALDH1A1KCNA3KDM4EPOLBTSHR | |
| SCHEMBL741364 | 0.75 | ALDH1A1 (0.81) | ALDH1A1LTA4H | |
| SCHEMBL72716 | 0.75 | ALDH1A1 (0.81) | ALDH1A1LTA4H | |
| SCHEMBL608225 | 0.75 | ALDH1A1 (0.81) | ALDH1A1LTA4H | |
| SCHEMBL844945 | 0.74 | HRH3 (0.43) | ALDH1A1KDM4EHTTMAPT | |
| SCHEMBL5380547 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4E | |
| SCHEMBL27933385 | 0.74 | CYP2D6 (0.41) | LTA4HHTT | |
| Water SCHEMBL2362659 | 0.73 | ALDH1A1 (0.78) | ALDH1A1LTA4H | |
| SCHEMBL844842 | 0.73 | HRH3 (0.47) | ALDH1A1KDM4EPOLBSMN1; SMN2HTT | |
| SCHEMBL28441867 | 0.72 | ALDH1A1 (0.57) | ALDH1A1KDM4ELTA4HHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140862-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-07-28 | — | — | EP | claimed |
| EP-1140871-A4 | THROMBIN OR FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-06 | — | — | EP | claimed |
| EP-1058549-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-12 | — | — | EP | claimed |
| US-20030004344-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2003-01-02 | — | — | US | claimed |
| US-6500855-B1 | NITROGEN CONTAINING AROMATIC HETEROCYCLES WITH ORTHO-SUBSTITUTED P1 GROUPS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-31 | — | — | US | claimed |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2002-08-22 | — | — | US | claimed |
| US-6403583-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | claimed |
| US-6369227-B1 | BLOOD COAGULATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-09 | — | — | US | claimed |
| EP-1140862-A1 | THROMBIN OR FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140871-A1 | THROMBIN OR FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1058549-A1 | THROMBIN OR FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-12-13 | — | — | EP | claimed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000039102-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038683-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| EP-1140862-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1140871-A4 | THROMBIN OR FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1058549-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039102-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038683-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004344-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | ALDH1A1 4139/4885KCNA3 2874/4885KDM4E 3805/4885 |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | ALDH1A1 4139/4885KCNA3 2874/4885KDM4E 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.